13F Pro

SEC Form 4 reporting owner

Mpm Bioventures 2018, L.P.

Mpm Bioventures 2018, L.P. has filed 19 Form 4 transactions reported between January 12, 2026 and September 9, 2026, as a reporting owner of Entrada Therapeutics, Inc. and a reporting owner of Aktis Oncology, Inc..

Name as filed: MPM BIOVENTURES 2018, L.P.

Open-market buys, 24 mo
$20.0M
1 lines
Open-market sales, 24 mo
$3.6M
12 lines
Companies
2
with Form 4 filings
Latest transaction
Sep 9, 2026
transaction date

Roles and reported holdings

  • TRDAEntrada Therapeutics, Inc.
    Aug 24, 2026 – Sep 9, 2026

    Reporting owner

    Held indirectly (latest line)3,885,115 sh as of Sep 9, 2026 · Form 4

    24 months: $3.6M sold

  • AKTSAktis Oncology, Inc.
    Jan 12, 2026

    Reporting owner

    Held indirectly (latest line)10,260,064 sh as of Jan 12, 2026 · Form 4

    24 months: $20.0M bought

Transaction history

All 19 reported transactions, newest first. Every row links to the Form 4 on SEC EDGAR.

DateCompanyTypeSharesValueFiling
Sep 9, 2026TRDAOpen-market saleCode S · indirectAlso reported by MPM BioVentures 2014, L.P.28,837$206K@ $7.13Form 4
Sep 8, 2026TRDAOpen-market saleCode S · indirectAlso reported by MPM BioVentures 2014, L.P.192,500$1.4M@ $7.41Form 4
Sep 4, 2026TRDAOpen-market saleCode S · indirectAlso reported by MPM BioVentures 2014, L.P.38,500$274K@ $7.11Form 4
Sep 3, 2026TRDAOpen-market saleCode S · indirectAlso reported by MPM BioVentures 2014, L.P.32,263$231K@ $7.17Form 4
Sep 2, 2026TRDAOpen-market saleCode S · indirectAlso reported by MPM BioVentures 2014, L.P.25,131$181K@ $7.19Form 4
Sep 1, 2026TRDAOpen-market saleCode S · indirectAlso reported by MPM BioVentures 2014, L.P.29,088$205K@ $7.06Form 4
Aug 31, 2026TRDAOpen-market saleCode S · indirectAlso reported by MPM BioVentures 2014, L.P.44,259$309K@ $6.99Form 4
Aug 28, 2026TRDAOpen-market saleCode S · indirectAlso reported by MPM BioVentures 2014, L.P.3,733$26K@ $7.01Form 4
Aug 27, 2026TRDAOpen-market saleCode S · indirectAlso reported by MPM BioVentures 2014, L.P.38,922$280K@ $7.20Form 4
Aug 26, 2026TRDAOpen-market saleCode S · indirectAlso reported by MPM BioVentures 2014, L.P.14,569$103K@ $7.06Form 4
Aug 25, 2026TRDAOpen-market saleCode S · indirectAlso reported by MPM BioVentures 2014, L.P.26,522$200K@ $7.54Form 4
Aug 24, 2026TRDAOpen-market saleCode S · indirectAlso reported by MPM BioVentures 2014, L.P.21,623$159K@ $7.34Form 4
Jan 12, 2026AKTSConversion of derivativeCode C · indirect6,000,000—Form 4
Jan 12, 2026AKTSConversion of derivativeCode C · indirect22,500,000—Form 4
Jan 12, 2026AKTSConversion of derivativeCode C · indirect5,000,000—Form 4
Jan 12, 2026AKTSOpen-market purchaseCode P · indirectAlso reported by GADICKE ANSBERT1,112,777$20.0M@ $18.00Form 4
Jan 12, 2026AKTSConversion of derivativeCode C · indirect1,577,119—Form 4
Jan 12, 2026AKTSConversion of derivativeCode C · indirect5,914,197—Form 4
Jan 12, 2026AKTSConversion of derivativeCode C · indirect1,314,262—Form 4

How this page is built

Every row comes from a Form 4 filed with the SEC, which officers, directors and holders of more than 10% of a company’s stock must file within two business days of a trade. Transactions are grouped by the reporting owner’s name as filed (spacing, capitals and punctuation ignored); two different people filing under an identical name would appear together, and one person filing under two spellings appears on two pages.

Open-market totals count code P purchases and code S sales over the last 24 months. The same trade reported on more than one filing is counted once; when another owner (for example a fund and its general partner) reports the identical trade, they are listed beside it. Holdings are the shares owned after the latest purchase, sale, gift or tax-withholding line, shown separately for direct and indirect ownership; an indirect figure is one holding line, not a total across every trust or entity.

This page describes what was filed with the SEC; it is not investment advice or a recommendation to buy or sell any security.